Form 8-K - Current report:
SEC Accession No. 0000950103-25-009025
Filing Date
2025-07-21
Accepted
2025-07-21 07:45:30
Documents
14
Period of Report
2025-07-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dp231799_8k.htm   iXBRL 8-K 27252
2 EXHIBIT 99.1 dp231799_ex9901.htm EX-99.1 11595
6 GRAPHIC image_001.gif GRAPHIC 1663
  Complete submission text file 0000950103-25-009025.txt   209259

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE amrx-20250721.xsd EX-101.SCH 3008
4 XBRL LABEL FILE amrx-20250721_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE amrx-20250721_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT dp231799_8k_htm.xml XML 3576
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 251135731
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)